IVO’s Skyware division clinches major European deal, more to come

|

Published 08-JAN-2018 11:07 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Leading data and analytics solutions company, Invigor Group (ASX:IVO), today announced that its logistics and workforce management solutions division, Skyware Service Control, has inked a contract for logistics support with one of Europe’s largest food retailers.

An initial contract valued at AU$100,000 has been secured for the first quarter of the year for the client’s technical service division in Germany. Further to that, a contract of greater scope, geography and value is currently being negotiated.

This development follows IVO’s expansion of Skyware into the Asia Pacific region, as the company announced in December last year.

Skyware has a high-impact footprint in numerous industries, including long-term contracts with leading blue-chip customers like Daimler (automotive), Liberty Global (telco) and Deutsche Bahn (transportation). It is now being actively sought by a range of companies that recognise the cloud-based technology’s cost-saving capabilities in workforce management and transport logistics, including ‘last mile’ deliveries.

The Skyware order pipeline for 2018 continues to gain traction, and now includes a substantial contract in negotiation within the healthcare sector – one of the numerous industries that require improved cloud-based logistics support.

Given recent tendering activity and expansion, IVO anticipates that the Skyware business is well on track to meet the revenue target of $2 million for the calendar year, and with substantial growth thereafter.

This is a speculative statement at the moment, so investors should seek professional financial advice for further information if considering this stock for their portfolio.

IVO CEO, Gary Cohen, said: “What we anticipated just a few weeks ago regarding Skyware’s growth potential is already being realised with this new contract and the substantial growth in the order book and pipeline. The potential growth for this division is enormous.”

“Starting the year with such a great contract with a recognised blue-chip food retailer reinforces the value of the Skyware technology, which addresses fundamental ecommerce logistics processes that need to be optimised in many organisations and industries,” said Cohen.

“We anticipate the contract’s scope and value will grow very materially. We are witnessing a lot of opportunity for Skyware not only in workforce management optimisation, but also in transport logistics and ‘last mile’ deliveries. We will report on more contract wins shortly.”

IVO’s order book across all divisions is strengthening, with further contracts imminent. The company also expects to soon announce a major new contract for its data and analytics solutions division for a large deployment in Asia.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X